PACAP38 Suppresses Cortical Damage in Mice with Traumatic Brain Injury by Enhancing Antioxidant Activity

Journal of Molecular Neuroscience

Volumn 54, Issue 3, 2014, Pages 370-379

  Miyamoto, Kazuyuki ^a   Tsumuraya, Tomomi ^a   Ohtaki, Hirokazu ^a   Dohi, Kenji ^a   Satoh, Kazue ^a   Xu, Zhifang ^a   Tanaka, Sachiko ^b   Murai, Norimitsu ^a   Watanabe, Jun ^a   Sugiyama, Koichi ^a   Aruga, Tohru ^a   Shioda, Seiji ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHOWA UNIVERSITY   (Japan)

Author keywords

Antioxidant enzyme; Glutathione peroxidase 1 (GPx 1); Mn SOD); PACAP38; Superoxide dismutase 2 (SOD 2; Traumatic brain injury (TBI)

Indexed keywords

GLUTATHIONE PEROXIDASE; GLUTATHIONE PEROXIDASE 1; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; MANGANESE SUPEROXIDE DISMUTASE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ANIMAL; BRAIN INJURIES; C57BL MOUSE; DRUG EFFECTS; MALE; METABOLISM; MOUSE; NEOCORTEX; OXIDATIVE STRESS;

ANIMALS; BRAIN INJURIES; GLUTATHIONE PEROXIDASE; MALE; MICE; MICE, INBRED C57BL; NEOCORTEX; OXIDATIVE STRESS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE;

EID: 84939895556     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-014-0309-4     Document Type: Article

References (44)

1. Abad C, Martinez C, Leceta J et al (2002) Pituitary adenylate-cyclase-activating polypeptide expression in the immune system. Neuroimmunomodulation 10:177–186
2. Arimura A, Li M, Batuman V (2006) Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury. Blood 107:661–668
3. Brown AW, Elovic EP, Kothari S et al (2008) Congenital and acquired brain injury. 1. Epidemiology, pathophysiology, prognostication, innovative treatments, and prevention. Arch Phys Med Rehabil 89:S3–S8
4. Crack PJ, Taylor JM, Flentjar NJ et al (2001) Increased infarct size and exacerbated apoptosis in the glutathione peroxidase-1 (Gpx-1) knockout mouse brain in response to ischemia/reperfusion injury. J Neurochem 78:1389–1399
5. Crack PJ, Taylor JM, de Haan JB et al (2003) Glutathione peroxidase-1 contributes to the neuroprotection seen in the superoxide dismutase-1 transgenic mouse in response to ischemia/reperfusion injury. J Cereb Blood Flow Metab 23:19–22
6. Delgado M, Ganea D (2001) Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. J Immunol 167:966–975
7. Dohi K, Satoh K, Mihara Y et al (2006) Alkoxyl radical-scavenging activity of edaravone in patients with traumatic brain injury. J Neurotrauma 23:1591–1599
8. Dohi K, Ohtaki H, Nakamachi T et al (2010) Gp91phox (NOX2) in classically activated microglia exacerbates traumatic brain injury. J Neuroinflammation 7:41
9. Farkas O, Tamás A, Zsombok A et al (2004) Effects of pituitary adenylate cyclase activating polypeptide in a rat model of traumatic brain injury. Regul Pept 123:69–75
10. Flynn JM, Melov S (2013) SOD2 in mitochondrial dysfunction and neurodegeneration. Free Radic Biol Med 62:4–12
11. Frechilla D, García-Osta A, Palacios S et al (2001) BDNF mediates the neuroprotective effect of PACAP-38 on rat cortical neurons. Neuroreport 12:919–923
12. Ganea D, Delgado M (2002) Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Crit Rev Oral Biol Med 13:229–237
13. Gasz B, Rácz B, Roth E et al (2006) Pituitary adenylate cyclase activating polypeptide protects cardiomyocytes against oxidative stress-induced apoptosis. Peptides 27:87–94
14. Kövesdi E, Tamás A, Reglodi D et al (2008) Posttraumatic administration of pituitary adenylate cyclase activating polypeptide in central fluid percussion injury in rats. Neurotox Res 13:71–78
15. Lebovitz RM, Zhang H, Vogel H et al (1996) Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc Natl Acad Sci U S A 93:9782–9787
16. Lewén A, Matz P, Chan PH (2000) Free radical pathways in CNS injury. J Neurotrauma 17:871–890
17. Manno EM, Rabinstein AA, Wijdicks EF et al (2008) A prospective trial of elective extubation in brain injured patients meeting extubation criteria for ventilatory support: a feasibility study. Crit Care 12:R138
18. Mao SS, Hua R, Zhao XP et al (2012) Exogenous administration of PACAP alleviates traumatic brain injury in rats through a mechanism involving the TLR4/MyD88/NF-κB pathway. J Neurotrauma 29:1941–1959
19. Martinez C, Abad C, Delgado M et al (2002) Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. Proc Natl Acad Sci U S A 99:1053–1058
20. Miyamoto K, Ohtaki H, Dohi K et al (2013) Therapeutic time window for edaravone treatment of traumatic brain injury in mice. Biomed Res Int 2013:379206
21. Miyata A, Arimura A, Dahl RR et al (1989) Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164:567–574
22. Mori H, Nakamachi T, Ohtaki H et al (2010) Cardioprotective effect of endogenous pituitary adenylate cyclase-activating polypeptide on Doxorubicin-induced cardiomyopathy in mice. Circ J 74:1183–1190
23. Nakamachi T, Tsuchida M, Kagami N et al (2012) IL-6 and PACAP receptor expression and localization after global brain ischemia in mice. J Mol Neurosci 48:518–525
24. Ohtaki H, Nakamachi T, Dohi K et al (2006) Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6. Proc Natl Acad Sci U S A 103:7488–7493
25. Ohtaki H, Nakamachi T, Dohi K et al (2008) Role of PACAP in ischemic neural death. J Mol Neurosci 36:16–25
26. Ohtaki H, Satoh A, Nakamachi T et al (2010) Regulation of oxidative stress by pituitary adenylate cyclase-activating polypeptide (PACAP) mediated by PACAP receptor. J Mol Neurosci 42:397–403
27. Park E, Bell JD, Siddiq IP et al (2009) An analysis of regional microvascular loss and recovery following two grades of fluid percussion trauma: a role for hypoxia-inducible factors in traumatic brain injury. J Cereb Blood Flow Metab 29:575–584
28. Rácz B, Gasz B, Borsiczky B et al (2007) Protective effects of pituitary adenylate cyclase activating polypeptide in endothelial cells against oxidative stress-induced apoptosis. Gen Comp Endocrinol 153:115–123
29. Ravni A, Eiden LE, Vaudry H et al (2006) Cycloheximide treatment to identify components of the transitional transcriptome in PACAP-induced PC12 cell differentiation. J Neurochem 98:1229–1241
30. Reglodi D, Somogyvari-Vigh A, Vigh S et al (2000a) Neuroprotective effects of PACAP38 in a rat model of transient focal ischemia under various experimental conditions. Ann N Y Acad Sci 921:119–128
31. Reglodi D, Somogyvari-Vigh A, Vigh S et al (2000b) Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. Stroke 31:1411–1417
32. Reglodi D, Tamás A, Somogyvári-Vigh A et al (2002) Effects of pretreatment with PACAP on the infarct size and functional outcome in rat permanent focal cerebral ischemia. Peptides 23:2227–2234
33. Reglodi D, Kiss P, Lubics A et al (2011) Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo. Curr Pharm Des 17:962–972
34. Reglodi D, Kiss P, Szabadfi K et al (2012) PACAP is an endogenous protective factor-insights from PACAP-deficient mice. J Mol Neurosci 48:482–492
35. Skoglösa Y, Lewén A, Takei N et al (1999) Regulation of pituitary adenylate cyclase activating polypeptide and its receptor type 1 after traumatic brain injury: Comparison with brain-derived neurotrophic factor and the induction of neuronal cell death. Neuroscience 90:235–247
36. Tamás A, Zsombok A, Farkas O et al (2006) Postinjury administration of pituitary adenylate cyclase activating polypeptide (PACAP) attenuates traumatically induced axonal injury in rats. J Neurotrauma 23:686–695
37. Tamas A, Reglodi D, Farkas O et al (2012) Effect of PACAP in central and peripheral nerve injuries. Int J Mol Sci 13:8430–8448
38. Tan YV, Abad C, Lopez R et al (2009) Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 106:2012–2017
39. Tanaka J, Koshimura K, Murakami Y et al (1997) Neuronal protection from apoptosis by pituitary adenylate cyclase-activating polypeptide. Regul Pept 72:1–8
40. Tsuchikawa D, Nakamachi T, Tsuchida M et al (2012) Neuroprotective effect of endogenous pituitary adenylate cyclase-activating polypeptide on spinal cord injury. J Mol Neurosci 48:508–517
41. Uchida D, Arimura A, Somogyvári-Vigh A et al (1996) Prevention of ischemia-induced death of hippocampal neurons by pituitary adenylate cyclase activating polypeptide. Brain Res 736:280–286
42. van Landeghem FK, Weiss T, Oehmichen M et al (2007) Cellular localization of pituitary adenylate cyclase-activating peptide (PACAP) following traumatic brain injury in humans. Acta Neuropathol 113:683–693
43. Vaudry D, Pamantung TF, Basille M et al (2002) PACAP protects cerebellar granule neurons against oxidative stress-induced apoptosis. Eur J Neurosci 15:1451–1460
44. Waschek JA (2013) VIP and PACAP: Neuropeptide modulators of CNS inflammation, injury, and repair. Br J Pharmacol 169:512–523